ReviewNature reviews. Cardiology2015
Treatment of pulmonary arterial hypertension in children.
Review in Nature reviews. Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children.BMC pediatrics · 2026Article
- Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry.European heart journal. Quality of care & clinical outcomes · 2024Article
- Systemic sclerosis-associated pulmonary arterial hypertension in children.Cardiovascular diagnosis and therapy · 2021Review
- Effects of exercise training on heart rate variability in children and adolescents with pulmonary arterial hypertension: a pilot study.Cardiovascular diagnosis and therapy · 2021Article
- In vivo assessment of a single adenine mutation in 5'UTR of Endothelin-1 gene in paediatric cases with severe pulmonary hypertension: an observational study.BMC research notes · 2021Observational
- Focused Update on Pulmonary Hypertension in Children-Selected Topics of Interest for the Adult Cardiologist.Medicina (Kaunas, Lithuania) · 2020Review
- Tribbles Homolog 3-Mediated Vascular Insulin Resistance Contributes to Hypoxic Pulmonary Hypertension in Intermittent Hypoxia Rat Model.Frontiers in physiology · 2020Article
- The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction.International journal of medical sciences · 2020Article
- Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.Journal of endocrinological investigation · 2019Article
- Impact of the Right Ventricular Sokolow-Lyon Index in Children with Idiopathic Pulmonary Arterial Hypertension.Pediatric cardiology · 2018Article
- Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery.Molecular pharmaceutics · 2018Article
- Treatment of Pediatric Pulmonary Hypertension.Current treatment options in cardiovascular medicine · 2018Review
- Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease.Pediatric cardiology · 2017Article
- Home Exercise Training in Children and Adolescents with Pulmonary Arterial Hypertension: A Pilot Study.Pediatric cardiology · 2017Article
- Challenges and opportunities in treating inflammation associated with pulmonary hypertension.Expert review of cardiovascular therapy · 2016Review
- "Nihilism" of chronic heart failure therapy in children and why effective therapy is withheld.European journal of pediatrics · 2016Review
- Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension.Experimental & molecular medicine · 2015Review
- ACE2-angiotensin-(1-7)-Mas axis might be a promising therapeutic target for pulmonary arterial hypertension.Nature reviews. Cardiology · 2015Article
- Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension.Drug, healthcare and patient safety · 2015Review
- Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension.Frontiers in pediatrics · 2015Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is an important cause of morbidity and mortality in children. Improved understanding of the pathophysiological mechanisms of the underlying diseases has resulted in the development of effective, but not yet curative, therapies. Currently, drugs from three main pharmacological groups targeting specific aberrant pathways (endothelin, nitric oxide, and prostacyclin) and four routes of administration (inhaled, intravenous, oral, and subcutaneous) have been approved for adult patients with PAH. However, only a minority of these drugs has been officially approved for children, mainly because randomized controlled studies are limited by the small number of paediatric patients with PAH worldwide. In children with progressive, severe PAH and an inadequate response to drug therapy, advances in interventional and surgical approaches have provided promising new strategies to avoid right ventricular deterioration. These techniques can delay or even avoid the need for lung transplantation. In this Review, we present an update on developments in drug therapy for patients with PAH and highlight the current status of these treatments in children. We also describe the new surgical, interventional, and hybrid procedures, as well as their practical application in children with severe PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.